Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain

Table 3 Mean change of eGFR during ERT in 30 male and 27 female patients per CKD stage

CKD stage at start of ERT	Males			Females
	N	eGFR change ± SE/year	p-value	N	eGFR change ± SE/year	p-value
at increased risk for CKD **(=GFR > 60, no microalbuminuria or proteinuria)	7	-2.5 ± 0.4*	<0.001	6	-1.0 ± 0.5*	0.05
CKD1 (=GFR > 90 and microalbuminuria)	10	-4.5 ± 0.4*	<0.001	7	-1.3 ± 0.7	0.07
CKD2 (=GFR 60-90 and microalbuminuria)	4	-2.1 ± 0.3	<0.001	10	-0.3 ± 0.3	0.25
CKD3 (=GFR30-60)	6	-4.1 ± 0.2	<0.001	3	-1.4 ± 0.5	0.015
CKD4(=GFR 15-30)	3	-2.0 ± 0.2	<0.001	1	-3.5 ± 0.3	-
CKD5 (=GFR < 15)	0			0

M = male, F = female. * eGFR change without hyperfiltration (GFR > 135 ml/min/1.73 m²) in males: at increased risk for CKD** (5M): -2.2 ± 0.4 ml/min/1.73 m² (p < 0.001), CKD 1 (7M) -3.4 ± 0.4 ml/min/1.73 m² (p < 0.001) and in females: at increased risk for CKD** (5F): 0.9 ± 0.5 (p = 0.06). ** at increased risk for CKD according to CKD guidelines. The p-value indicates whether the change in renal function is significant.

ISSN: 1750-1172